Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1 (5-Year IF – 2.0)
Journal Citation Indicator (JCI) (2023) – 0.4
Scopus CiteScore – 3.7 (CiteScore Tracker – 4.1)
Index Copernicus  – 171.00; MNiSW – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2018, vol. 27, nr 10, October, p. 1329–1339

doi: 10.17219/acem/70430

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Cord blood-derived mesenchymal stem cells with hepatogenic differentiation potential ameliorate chronic liver affection in experimental models

Manal M. Kamel1,A,B,D,E, Hanan G. El Baz1,A,B,C, Zeinab Demerdash1,A,B,C,F, Salwa Hassan1,B, Faten Salah1,B, Wafaa A. Mansour1,B,C, Olfat Hammam2,B,C, Shimaa Atta1,B,C, Ali Bayoumi1,B,C, Marwa Hassan1,C,D,E, Soheir Mahmoud3,B

1 Department of Immunology, Theodor Bilharz Research Institute, Giza, Egypt

2 Department of Pathology, Theodor Bilharz Research Institute, Giza, Egypt

3 Department of Parasitology, Theodor Bilharz Research Institute, Giza, Egypt

Abstract

Background. The liver is one of the major target organs for which cell-based therapies are very promising. The limitations of various cellular therapies, including bone marrow (BM)-derived mesenchymal stem cells (MSCs), urges the exploration of stem cell sources more suitable for transplantation. Human umbilical cord blood (HUCB) can overcome these drawbacks with a favorable reparative outcome.
Objectives. The aim of this study was to evaluate the therapeutic potential of MSCs in 2 groups of chronic liver injury experimental models.
Material and Methods. Propagation and characterization of MSCs isolated from cord blood (CB) samples were performed and differentiation into osteogenic, adipogenic and hepatogenic lineages was induced. The 1st experimental model group (80 mice) included a negative control, a pathological control and 60 mice infected with Schistosoma mansoni (S. mansoni) and transplanted with MSCs. The 2nd experimental model group (30 hamsters) included 10 healthy hamsters serving as a negative control and 20 hamsters injected with repeated doses of carbon tetrachloride (CCl4) to induce liver fibrosis; 10 of them were treated with an intrahepatic (IH) injection of 3 × 106 MSCs and the other 10 were untreated pathological controls. Mice and hamsters were sacrificed 12 weeks post-transplantation and their liver sections were stained immunohistochemically for the detection of human hepatocyte-like cells. Moreover, the sections were examined for the levels of fibrosis.
Results. In both models, the transplantation of CB-derived MSCs (CB-MSCs) resulted in the engraftment of the fibrotic livers with newly formed hepatocytes, as evidenced by positive immunohistochemistry staining with human Hepatocyte Paraffin 1 (Hep Par 1), alpha-fenoprotein (AFP), cytokeratin 18 (CK18), cytokeratin 7 (CK7), and OV6 monoclonal antibody. The transplanted liver sections showed markedly reduced hepatic fibrosis with a significantly lower fibrotic index, as well as significantly improved liver functions compared to the pathological control (p < 0.001).
Conclusion. This data provides hope that human CB-MSCs can be utilized as multipotent stem cells with unlimited potentiality in regenerative medicine and supports the concept of cellular therapy for the cure of hepatic fibrosis.

Key words

cord blood, mesenchymal stem cells, carbon tetrachloride, liver fibrosis

References (40)

  1. Pellicoro A, Ramachandran P, Iredale JP, Fallowfield JA. Liver fibrosis and repair: Immune regulation of wound healing in a solid organ. Nat Rev Immunol. 2014;14(3):181–194.
  2. Zhao W, Li J, Cao D, et al. Intravenous injection of mesenchymal stem cells is effective in treating liver fibrosis. World J Gastroenterol. 2012;18(10):1048–1058.
  3. Hua J, Qiu P, Zhu H. Multipotent mesenchymal stem cells (MSCs) from human umbilical cord: Potential differentiation of germ cells. Afr J Biochem Res. 2011;5:113–123.
  4. Prasajak P, Leeanansaksiri W. Mesenchymal stem cells: Current clinical applications and therapeutic potential in liver diseases. J Bone Marrow Res. 2014;2:137.
  5. Kögler G, Sensken S, Airey JA, et al. A new human somatic stem cell from placental cord blood with intrinsic pluripotent differentiation potential. J Exp Med. 2004;200(2):123–135.
  6. Kögler G, Radke TF, Lefort A, et al. Cytokine production and hematopoiesis supporting activity of cord blood-derived unrestricted somatic stem cells. Exp Hematol. 2005;33(5):573–583.
  7. Acosta S, Franzese N, Staples M, et al. Human umbilical cord blood for transplantation therapy in myocardial infarction. J Stem Cell Res Ther. 2013;4(Suppl 4):S4–005.
  8. Banas A, Teratani T, Yamamoto Y, et al. IFATS collection: In vivo therapeutic potential of human adipose tissue mesenchymal stem cells after transplantation into mice with liver injury. Stem Cells. 2008;26(10):2705–2712.
  9. Tsai PC, Fu TW, Chen YM, et al. The therapeutic potential of human umbilical mesenchymal stem cells from Wharton’s jelly in the treatment of rat liver fibrosis. Liver Transpl. 2009;15(5):484–495.
  10. Broxmeyer HE, Douglas GW, Hangoc G, et al. Human umbilical cord blood as a potential source of transplantable hematopoietic stem/progenitor cells. Proc Natl Acad Sci USA. 1989;86(10):3828–3832.
  11. Kögler G, Callejas J, Hakenberg P, et al. Hematopoietic transplant potential of unrelated cord blood: Critical issues. J Hematother. 1996;5(2):105–116.
  12. Zaibak F, Bello P, Kozlovski J, et al. Unrestricted somatic stem cells from human umbilical cord blood grow in serum-free medium as spheres. BMC Biotechnol. 2009;9:101.
  13. Demerdash Z, El Baz H, Mahmoud F, et al. Enhancing ex vivo expansion of cord blood-derived unrestricted somatic stem cells for clinical applications. Cell Prolif. 2013;46(6):628–636.
  14. Waclawczyk S, Buchheiser A, Flögel U, Radke TF, Kögler G. In vitro differentiation of unrestricted somatic stem cells into functional hepatic-like cells displaying a hepatocyte like glucose metabolism. J Cell Physiol. 2010;225(2):545–554.
  15. Moharib MN, Hammam OA, Salman FH, El-naggar MM, Sherif SA. Transplantation of modified and fresh hepatocyte reduces hepatotoxicity induced by carbon tetrachloride. Life Sci J. 2014;11:641–649.
  16. German G, Hytiroglou P, Fotiadu A, Burroughs A, Dhillon A. Assessment of fibrosis and cirrhosis in liver biopsies. Semin Liver Dis. 2011;31(1):82–90.
  17. Tsai CC, Hung SC. Functional roles of pluripotency transcription factors in mesenchymal stem cells. Cell Cycle. 2012;11(20):3711–3712.
  18. Foroutan T, Sadeghizadeh M. Lower oncogenic potential of human mesenchymal stem cells derived from cord blood compared to bone marrow and adipose tissues. Indian J Appl Res. 2014;4(9):23–27.
  19. Liang XJ, Chen XJ, Yang DH, Huang SM, Sun GD, Chen YP. Differentiation of human umbilical cord mesenchymal stem cells into hepatocyte-like cells by hTERT gene transfection in vitro. Cell Biol Int. 2012;36(2):215–221.
  20. Li D, Fan J, He X, et al. Therapeutic effect comparison of hepatocyte-like cells and bone marrow mesenchymal stem cells in acute liver failure of rats. Int J Clin Exp Pathol. 2015;8(1):11–24.
  21. Hong J, Jin H, Han J, et al. Infusion of human umbilical cord derived mesenchymal stem cells effectively relieves liver cirrhosis in DEN induced rats. Mol Med Rep. 2014;9(4):1103–1111.
  22. Li J, Zhang L, Xin J, et al. Immediate intraportal transplantation of human bone marrow mesenchymal stem cells prevents death from fulminant hepatic failure in pigs. Hepatology. 2012;56(3):1044–1052.
  23. Shams S, Mohsin S, Nasir GA, Khan M, Khan SN. Mesenchymal stem cells pretreated with HGF and FGF4 can reduce liver fibrosis in mice. Stem Cells Int. 2015;2015:747245.
  24. Yang JF, Cao HC, Pan QL, Yu J, Li J, Li LJ. Mesenchymal stem cells from the human umbilical cord ameliorate fulminant hepatic failure and increase survival in mice. Hepatobiliary Pancreat Dis Int. 2015;14(2):186–193.
  25. Park M, Kim YH, Woo SY, et al. Tonsil-derived mesenchymal stem cells ameliorate CCl4-induced liver fibrosis in mice via autophagy activation. Sci Rep. 2015;5:8616.
  26. Salem HK and Thiemermann C. Mesenchymal stromal cells: Current understanding and clinical status. Stem Cells. 2010;28(3):585–596.
  27. Ley K, Laudanna C, Cybulsky MI, Nourshargh S. Getting to the site of inflammation: The leukocyte adhesion cascade updated. Nat Rev Immunol 2007;7(9):678–689.
  28. Honczarenko M, Le Y, Swierkowski M, Ghiran I, Glodek AM, Silberstein LE. Human bone marrow stromal cells express a distinct set of biologically functional chemokine receptors. Stem Cells. 2006;24(4):1030–1041.
  29. Ringe J, Strassburg S, Neumann K, et al. Towards in situ tissue repair: Human mesenchymal stem cells express chemokine receptors CXCR1, CXCR2 and CCR2, and migrate upon stimulation with CXCL8 but not CCL2. J Cell Biochem. 2007;101(1):135–146.
  30. Liu WH, Song FQ, Ren LN, et al. The multiple functional roles of mesenchymal stem cells in participating in treating liver diseases. J Cell Mol Med. 2015;19(3):511–520.
  31. Banas A, Teratani T, Yamamoto Y, et al. Rapid hepatic fate specification of adipose-derived stem cells and their therapeutic potential for liver failure. J Gastroenterol Hepatol. 2009;24(1):70–77.
  32. Prosser CC, Yen RD, Wu J. Molecular therapy for hepatic injury and fibrosis: Where are we? World J Gastroenterol. 2006;12(4):509–515.
  33. George J, Rao KR, Stern R, Chandrakasan G. Dimethylnitrosamine-induced liver injury in rats: The early deposition of collagen. Toxicology. 2001;156(2–3):129–138.
  34. Matsuda-Hashii Y, Takai K, Ohta H, et al. Hepatocyte growth factor plays roles in the induction and autocrine maintenance of bone marrow stromal cell IL-11, SDF-1 alpha, and stem cell factor. Exp Hematol. 2004;32(10):955–961.
  35. Pan RL, Wang P, Xiang LX, Shao JZ. Delta-like1 serves as a new target and contributor to liver fibrosis down-regulated by mesenchymal stem cell transplantation. J Biol Chem. 2011;286(14):12340–12348.
  36. Abdel Aziz MT, Atta HM, Roshdy NK, et al. Amelioration of murine Schistosoma mansoni induced liver fibrosis by mesenchymal stem cells. J Stem Cells Regen Med. 2012;8(1):28–34.
  37. Kuo TK, Hung SP, Chuang CH, et al. Stem cell therapy for liver disease: Parameters governing the success of using bone marrow mesenchymal stem cells. Gastroenterology. 2008;134(7):2111–2121.
  38. Hayashi H, Sakai T. Animal models for the study of liver fibrosis: New insights from knockout mouse models. Am J Physiol Gastrointest Liver Physiol. 2011;300(5):G729–738.
  39. Chensue SW, Boros DL. Modulation of granulomatous hypersensitivity. I. Characterization of T lymphocytes involved in the adoptive suppression of granuloma formation in Schistosoma mansoni-infected mice. J Immunol. 1979;123(3):1409–1414.
  40. Cheever AW, Lenzi JA, Lenzi HL, Andrade ZA. Experimental models of Schistosoma mansoni infection. Mem Inst Oswaldo Cruz. 2002;97(7):917–940.
© Wroclaw Medical University